| TAVI | aortic stenosis, in all type of patients | vs standard therapy | by 38% | by 138% | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.62 [0.40 0.95] | p=0.04 | 0 | 358 | 1 | PARTNER, | | stroke or TIA | 2.38 [1.01 5.58] | p=0.04 | 0 | 358 | 1 | PARTNER, | | Death from any cause or major stroke | 0.66 [0.43 1.01] | p=1.00 | 0 | 358 | 1 | PARTNER, | | major stroke | 2.00 [0.79 5.08] | p=1.00 | 0 | 358 | 1 | PARTNER, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PARTNER, 2010 | transcatheter aortic-valve
implantation (TAVI)with Edwards SAPIEN Transcatheter Heart Valve
| standard therapy | patients with severe aortic stenosis considered
not to be suitable candidates for surgery |
|
| TAVI | aortic stenosis, in all type of patients | vs surgical valve replacement | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke or TIA | no data | | Death from any cause or major stroke | no data | | major stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PARTNER cohort A, 2011 | percutaneous valve implantation (Sapien device) | surgical valve replacement
| high risk, symptomatic patients with severe aortic stenosis |
|
